news

CUPERTINO, Calif., July 7 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) today reported that King Pharmaceuticals, Inc. (NYSE: KG) and Pain Therapeutics, Inc. (Nasdaq: PTIE) have announced that King met with the Food and Drug Administration (FDA) on July 2, 2009 to discuss the Complete Response Letter regarding the New Drug Application (NDA) for REMOXY(R). According […]

CUPERTINO, Calif., June 16 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Joseph Stauffer has joined DURECT as Chief Medical Officer and Executive Vice President, Corporate Strategy. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) “Dr. Stauffer’s successful leadership of clinical research and medical affairs for pain products while at Alpharma and Abbott, and first-hand experience with the regulatory

CUPERTINO, Calif., May 6 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2009. Total revenues were $6.2 million for the three months ended March 31, 2009, compared to $6.4 million for the same period in 2008. Net loss for the three months ended March 31, 2009

CUPERTINO, Calif., April 28 /PRNewswire-FirstCall/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) first quarter 2009 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Wednesday, May 6, 2009 at 4:30 pm Eastern Time (1:30 pm Pacific Time). A live audio webcast

CUPERTINO, Calif., March 16 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today positive results from a 74 patient Phase IIb clinical trial conducted by Endo Pharmaceuticals of TRANSDUR(TM)-Sufentanil, a proprietary seven day patch under development for the treatment of chronic pain. The development program for this drug candidate was reviewed with the U.S. Food and

CUPERTINO, Calif., March 9 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that Matthew Hogan, Chief Financial Officer, will be presenting at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009 at 8:00 a.m. EDT. The conference is being held at the Marriott Hotel in Boston. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) A live audio webcast

CUPERTINO, Calif., Feb. 27 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) today reported that Endo Pharmaceuticals (Nasdaq: ENDP) has given notice that it is returning to us Endo’s rights in the U.S. and Canada to develop and commercialize TRANSDUR(TM)-Sufentanil, a proprietary transdermal patch in development intended to treat chronic pain. Endo and DURECT recently completed a

CUPERTINO, Calif., Feb. 9 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2008. Total revenues were $6.6 million for the three months ended December 31, 2008 and December 31, 2007. Net loss for the three months ended December 31, 2008 was $19.5 million, compared

CUPERTINO, Calif., Feb. 2 /PRNewswire-FirstCall/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) fourth quarter 2008 financial results press release, you are invited to listen to the conference call that will be broadcast live over the Internet on Monday, February 9th, 2009 at 4:30 p.m. EST (1:30 PST). (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) A live audio webcast of

CUPERTINO, Calif., Dec. 11 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) today reported that Pain Therapeutics, Inc. (Nasdaq: PTIE) has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for REMOXY(R), an abuse-resistant controlled-release form of oxycodone. Based on its review, the FDA has determined that